Protalix (PLX) Form 4: Director awarded shares and long-dated options
Rhea-AI Filing Summary
Bar-Shalev Amos, a director of Protalix BioTherapeutics, Inc. (PLX), reported transactions on 09/03/2025. He was awarded 7,500 restricted shares under the companys Amended and Restated 2006 Stock Incentive Plan; those shares are registered in a trustee to meet Israeli Section 102 requirements and vest in 12 equal quarterly installments, with accelerated vesting on a corporate transaction or change in control. He also received a grant of 15,000 stock options with a $1.64 exercise price exercisable from 09/03/2025 and expiring 09/03/2035. Following the transactions the reporting person beneficially owns 7,500 shares indirectly and directly holds 15,000 option-based shares. The Form notes a separate disposition of 168 shares. The filing was signed by an attorney-in-fact on 09/04/2025.
Positive
- 7,500 restricted shares awarded under the companys amended 2006 Stock Incentive Plan
- 15,000 stock options granted with a $1.64 exercise price and a 2035 expiration, providing long-term incentive alignment
- Securities registered in trustee to qualify for Israeli Section 102 tax treatment, as disclosed
Negative
- None.
Insights
TL;DR: Director received equity and options, but amounts are modest relative to a public company and likely non-material to valuation.
The grant of 7,500 restricted shares and 15,000 options aligns with routine director/employee compensation under the company's long-standing equity plan. The restricted shares and options vest quarterly over three years, with customary accelerated vesting on a change in control. The exercise price of $1.64 establishes a cost basis for the options; the expiration in 2035 gives a long-term horizon. A small disposition of 168 shares was also reported. Overall, these are standard equity awards and disclosures with limited immediate impact on capital structure or liquidity.
TL;DR: Compensation grant follows established plan mechanics and Israeli tax registration; disclosure appears complete and timely.
The restricted shares are registered in a trustee to satisfy Section 102 tax treatment, which is a common practice for Israeli-domiciled participants. Vesting schedules and accelerated vesting on corporate transactions are explicitly disclosed, reflecting standard change-in-control protections. The filing identifies the reporting person as a director and was executed by an attorney-in-fact, consistent with Form 4 procedures. No governance red flags are evident from the disclosed items.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options (Right to Buy) | 15,000 | $0.00 | -- |
| Grant/Award | Common Stock | 7,500 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee. The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033.
